ABOUT RHYTHM
Pioneering a path forward at Rhythm
Pioneering a path forward at Rhythm
Rhythm Pharmaceuticals is a global commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Our people immerse themselves in our vision, mission and values so we can create innovations that achieve meaningful positive impact on those living with rare neuroendocrine diseases.
Our vision
Patients with rare neuroendocrine diseases are able to live their fullest lives and are transformed through optimal, stigma-free care.
Our mission
To transform the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
Our values
We are inspired to tackle tough challenges and have the courage to ask bold questions.
We are committed to advancing scientific understanding to improve patients’ lives.
We are eager to learn and adapt.
We believe collaboration and ownership are foundational for Rhythm’s success.
We value the unique contribution each individual brings to furthering our mission.
Our path to help transform the care of rare neuroendocrine diseases
Explore our step-by-step path forward:
Founded in Boston
First patients with rare melanocortin-4 receptor (MC4R) pathway diseases on treatment
Phase 2 results in POMC deficiency published in the New England Journal of Medicine
Initial Public Offering completed on Nasdaq
Phase 2 results in LEPR deficiency published in Nature Medicine
Phase 3 trial in POMC deficiency initiated
FDA approves precision medicine for the treatment of obesity and the control of hunger associated with for POMC and LEPR deficiency
European Commission authorizes precision medicine for the treatment of obesity and the control of hunger associated with POMC, PSCK1 and LEPR deficiency
Precision medicine approved for BBS in US and Europe
Xinvento acquired
Initiates Phase 3 trial in acquired hypothalamic obesity
First-ever patients dosed with RM-718
Acquired oral MC4R agonist LB54640 from LG Chem Life Sciences
Precision medicine approved for the treatment of acquired hypothalamic obesity (aHO) in US and Europe
Our locations
Rhythm international presence and partnerships
Legend
Rhythm Pharmaceuticals Finland
Rhythm Pharmaceuticals Norway
Rhythm Pharmaceuticals Sweden
Rhythm Pharmaceuticals Denmark
Rhythm Pharmaceuticals Ireland
Rhythm Pharmaceuticals Netherlands
Radarweg 29,
1043 NX Amsterdam
The Netherlands
Rhythm Pharmaceuticals UK Ltd
London
Rhythm Pharmaceuticals Belgium
Central and Eastern Europe (Exceed Orphan)
Rhythm Pharmaceuticals Luxembourg
Rhythm Pharmaceuticals France
121 rue d'Aguesseau – 92100 Boulogne-Billancourt
Rhythm Pharmaceuticals Austria
Rhythm Pharmaceuticals Germany
Maximilianstr. 35a, D-80539 München, Germany
Rhythm Pharmaceuticals Switzerland
Rhythm Pharmaceuticals Italy
Trispera
Izzet Pasa Mh. Yeni Yol Cd. Nurol Tower No:3/336 eOfis 34381 Sisli - Istanbul, Türkiye